For example, we aimed for >75% mask access. Equalizing by time (not distance) was fairer to rural people. For vaccination, we respected preferences (e.g., some elderly hesitant about AstraZeneca), and built dashboards showing age‑by‑district vaccine preferences. Some swore by BNT (procured with help from TSMC, our most trusted institution); others preferred the locally developed Medigen; others only Moderna. We turned “anti‑vax vs pro‑vax” polarization into a healthy “my soccer team vs yours” competition that kept attention on vaccination. There was little oxygen for anti‑vax politics in Taiwan. But again, targets were set by CECC; civic tech didn’t propose alternatives to vaccination—because legitimacy was high.